Search

Your search keyword '"Zhu, Hangju"' showing total 15 results
Start Over Author "Zhu, Hangju"
15 results on '"Zhu, Hangju"'

6. Improving the Lung Cancer Clinical Trial Development by Incorporating Competing Risk Factors

Author

Han Jing, Wang Li, Zhu Wenbo, Qing Rong, Zhao Qing, Feng Ji-feng, Zhang Junying, Shi Meiqi, and Zhu Hangju

Subjects
Oncology, Male, medicine.medical_specialty, Lung Neoplasms, Article Subject, medicine.medical_treatment, Kaplan-Meier Estimate, Competing risks, General Biochemistry, Genetics and Molecular Biology, Risk Factors, Internal medicine, medicine, Humans, Adverse effect, Lung cancer, Survival analysis, Aged, Chemotherapy, Clinical Trials as Topic, General Immunology and Microbiology, business.industry, Incidence, Cancer, General Medicine, Immunotherapy, Middle Aged, medicine.disease, Progression-Free Survival, Clinical trial, Disease Progression, Medicine, Female, business, Research Article
Abstract

Introduction. Distinct from other diseases, as cancer progresses, both the symptoms and treatments evolve, resulting in a complex, time-dependent relationship. Many competing risk factors influence the outcome of cancer. An improved method was used to evaluate the data from 6 non-small-cell lung cancer (NSCLC) clinical trials combined in our center since 2016 to deal with the bias caused by competing risk factors. Material and Methods. Data of 118 lung cancer patients were collected from 2016 to 2020. Fine and Gray’s model for competing risk was used to evaluate survival of different treatment group compares with the classic survival analysis model. Results. Immunotherapy had better progression-free survival than chemotherapy. (HR: 0.62, 95% CI: 0.41-0.95, p = 0.0260 ). However, there were no significant differences in patients who withdrew due to treatment-related adverse events from different groups. ( Z = 0.0508 , p = 0.8217 ). The PD-1/PD-L1 inhibitors in our study did not significantly improve overall survival compared with chemotherapy (HR:0.77, 95% CI:0.48-1.24, p = 0.2812 ), estimated 1-year overall survival rates were 55% and 46%, and 3-year overall survival rates were 17% and 10%, respectively. Conclusion. When the outcome caused by competing risk exists, the corresponding competing risk model method should be adopted to eliminate the bias caused by the classic survival analysis.

Published
2021

13. MicroRNA-224 modulates chemosensitivity of breast cancer cells to docetaxel by apoptosis inhibitor 5.

Author

Zhang J, Lu Y, Zhang Y, Chen Y, Zhu W, Zhu H, Wu J, and Tang J

Subjects
Antineoplastic Agents pharmacology, Apoptosis drug effects, Breast Neoplasms pathology, Female, Humans, Transfection, Antineoplastic Agents therapeutic use, Apoptosis Regulatory Proteins metabolism, Breast Neoplasms drug therapy, Docetaxel pharmacology, MicroRNAs metabolism, Nuclear Proteins metabolism
Abstract

Purpose: The view that microRNA-224 (miR-224) may lead to tumorigenesis has been accepted in many studies. However, its role remains unclear in modulating the chemosensitivity of breast cancer cells to docetaxel (DOC). Thus, the aim of this study was to estimate what's the role of miR-224 in the chemosensitivity of breast cancer cells to DOC., Methods: The role of miR-224 in breast cancer cells was analyzed using CCK-8 assay, real-time PCR, flow cytometry assay and Western blot. Dual-luciferase reporter assay and API-5-siRNA technology were performed to analyze the association between miR-224 and Apoptosis inhibitor 5 (API-5)., Results: Overexpression of miR-224 could significantly decrease the chemosensitivity of MCF-7 breast cancer cells to DOC. The luciferase activity of MCF-7/DOC cells containing wild-type 3'UTR of API-5 could be inhibited by miR-224 mimics. Similarly, the chemoresistance of MCF-7 cells to DOC induced by miR-224 mimics could be partially reversed by API-5-siRNA., Conclusion: An inverse association between miR-224 and API-5 in breast cancer cells was revealed. Dysregulation of miR-224 plays a vital role in the acquired DOC resistance of breast cancer and at least partially via targeting API-5.

Published
2021

15. [Determination of total Bromine in urine by inductively coupled plasma mass spectrometry (ICP-MS)].

Author

Zhou C, Zhu H, Liu D, Miao R, Ying L, and Zhu B

Subjects
Humans, Bromine urine, Mass Spectrometry
Abstract

Objective: To establish a method to determine total bromine in urine., Method: Diluted urine samples were directly introduced into ICP-MS then quantized by standard curve., Result: Total bromine in urine was linear within 1.0~50 mg/L with r > 0.999, When spiked at a concentration of 0.020 mg/L, 0.050 mg/L, 0.150 mg/L, the recovery was 95%~98%, intra-assay precision was 1.4% 3.2%, inter-assay precision was 3.4% to 5.0%. Urine could store in -20 °C refrigerator 3 months without any bromine loss., Conclusion: Using ICP-MS to determine the urinary total bromine, the method is fast, accurate, wide linear range of features, could meet with the requirement of Part 5 of occupational health standards guide: Method determination of chemical substances in biological materials (GBZ/T 210.5-2008), a strong competitive advantage in a wide range of survey, suitable for promotion.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results